VRTX : Analysis & Opinions

  1. Is the FDA Worried About Vertex's New Drug?

    March 31, 2015
    Vertex Pharmaceuticals' (NASDAQ: VRTX) first cystic fibrosis drug, Kalydeco, was approved nearly three months before the ...
  2. A Growing Label Drives Vertex's Transformation

    March 19, 2015
    In 2011, Vertex Pharmaceuticals (NASDAQ: VRTX) was biotech's shining star. The company's Invicek, a revolutionary new hepatitis ...
  3. Has The Time Come To Sell Vertex Pharmaceuticals?

    March 13, 2015
    While it's been a choppy ride for Vertex Pharmaceuticals investors, the stock has handily outperformed the broader market ...
  4. The Biggest Biotech Companies

    January 15, 2015
    These biotech firms want to revolutionize medicine. If successful, they may see high profits, but investing in these companies ...
  5. Big Swings in Biotech Short Interest

    October 13, 2014
  6. Biotechnology Stocks To Keep on the Radar

    April 23, 2014
    Health care is showing a resurgance, lead by biotechnology. Here are the opportunites to watch.
  7. Gilead Sciences Leads In Rising Short Interest Among Biotechs

    November 12, 2013
    Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Alexion Pharmaceuticals ...
  8. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, ...

    September 14, 2013
    Declining short interest in Alexion Pharmaceuticals (NASDAQ: PCYC) bucked the trend among leading biotech and emerging pharmaceutical ...
  9. Vertex Building A Fortress In Cystic Fibrosis

    August 28, 2013
    Vertex is in the early days of what could be a $10B franchise in cystic fibrosis treatment.
  10. Roche Delivering Leverage, But Still Needs Diversification

    July 29, 2013
    If Roche can balance out its sales mix, the long-term value could be quite compelling at present prices.
  11. Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, ...

    June 26, 2013
    Among biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG) and saw the most significant rise in short interest ...
  12. Fresenius Medical Care AG & Co and Other Big Movers In Healthcare ...

    November 1, 2012
    The Nasdaq has moved up 1.5%, the S&P 500 is trading up 1.1% and the Dow has risen 1.1%, marking a bad morning for the ...
  13. Amgen and Other Healthcare Stocks Making Big Moves on October ...

    October 19, 2012
    The market is having a bad day so far: the Nasdaq has slipped 1.6%; the S&P 500 is trading down 1%; and the Dow is down ...
  14. Eli Lilly Among Healthcare's Biggest Movers on August 27, 2012

    August 27, 2012
    The market is on the rise this morning. The Nasdaq is up 0.5%; the S&P 500 has risen 0.3%; and the Dow has climbed 0.1%. ...
  15. Novo Nordisk A/S (ADR) and Other Big Movers In Healthcare

    August 14, 2012
    The Nasdaq has climbed 0.6%, the S&P 500 is up 0.3% and the Dow has risen 0.3%, marking a bad morning for the market. ...
  16. Healthcare Sector's Biggest Movers: HCA Holdings and More

    August 6, 2012
    The market is currently up, with the Nasdaq climbing 1%, the S&P 500 rising 0.5% and the Dow up 0.6%. The healthcare ...
  17. NASDAQ's Top YTD Performers, Ex-Apple

    May 10, 2012
    The past week has been none too kind to the PowerShares QQQ (NASDAQ: QQQ), also known as the NASDAQ 100 tracking ETF. QQQ ...
  18. 15 Biotech Companies Waiting For FDA Approval

    March 21, 2012
    Despite all of these uncertainties, investors still heavily focus on whether a company's new drug will be approved by the ...
  19. The Long-Term Play In Lab Work

    January 16, 2012
    As drugmakers beef up their pipelines in this world of rising costs, the contract research sector should profit.
  20. Is Third Time The Charm For Gilead?

    November 22, 2011
    Gilead is going all in on Hep C, as it acquires Pharmasset in a massive deal.
  21. Top Performing Mid-Cap Stocks

    May 27, 2011
    These four top-performing stocks in the S&P MidCap 400 Index in 2011 are an interesting - and unexpected - mix.
  22. FDA Makes InterMune Sick

    May 10, 2010
    Should investors hang on despite a devastating FDA decision?
  23. Biotech ETFs Under The Microscope

    July 24, 2008
    Biotech ETFs have been immune to the falling stock market. We examine three top performing funds to find a surprising long-term ...
Trading Center